TY  - CHAP
M1  - Book, Section
TI  - Major Depressive Disorder
A1  - Teter, Christian J.
A1  - Kando, Judith C.
A1  - Wells, Barbara G.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
Y1  - 2017
N1  - 
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Content  UpdateAugust  15,  2019Brexanolone  (Zulresso)  for  Treatment  of  Postpartum  Depression  in  Adult  Women:  Brexanolone  is  a  neuroactive  steroid  and  GABAA  receptor  modulator  approved  for  treatment  of  postpartum  depression  in  adult  women.  Results  of  one  phase  II  and  two  phase  III  randomized,  double-blind,  placebo-controlled  clinical  trials  provide  evidence  for  the  efficacy  and  safety  of  brexanolone  compared  to  placebo  as  evidenced  by  reduction  in  HAM-D  scores.  Brexanolone  carries  a  black  box  warning  for  excessive  sedation  and  sudden  loss  of  consciousness  and  is  only  available  via  REMS  program  restriction.  The  treatment  requires  a  60-hour  continuous  intravenous  infusion  that  is  expected  to  cost  $34,000;  these  factors  will  limit  brexanolone  use  to  a  select  population  of  women  with  postpartum  depression.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1165100575
ER  -